All In Biotech

Drug Trial Radar · NCT06600581

Safety and Efficacy of IMM01-STEM Against Placebo on Muscle Performance in Seniors With Obesity and Muscle Weakness

Randomized Adaptive Study for Safety and Efficacy of Pluripotent Cell Secretome on Muscle Performance in Seniors With Sarcopenic Obesity

Last checked: Nov 19, 2026Latest source record: Jan 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

55

Planned (sponsor's estimate)

Start

Dec 19, 2024

Primary completion

Jul 15, 2026

Study completion Dec 15, 2026

Sponsor

Lead sponsor
Immunis, Inc.Industry
Sponsor type
Industry
First posted
Sep 19, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 60 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Placebo controlled study for safety and efficacy of IMM01-STEM on muscle performance in seniors with obesity and muscle weakness

Conditions

  • Muscle Performance
  • Sarcopenic Obesity

Interventions

  • IMM01-STEMBiological

    IMM01-STEM is an allogeneic cell-free secretome product derived from partially differentiated human stem cells derived from a pluripotent embryonic stem cell line that was established from a single donor IVF discarded blastocyst. The cells are cultivated in bioreactors and the product of their secretion is collected, purified and concentrated to a standardized formulation. The secretome contains a mixture of molecules related to immunomodulation, growth, and extracellular matrix remodeling. This intervention is given 2mL twice a week.

  • PlaceboOther

    Saline. This intervention is given 2mL twice a week.

  • IMM01-STEM alternating with placebo (saline)Biological

    This intervention consists of IMM01-STEM given once a week and placebo given one a week. IMM01-STEM is an allogeneic cell-free secretome product derived from partially differentiated human stem cells derived from a pluripotent embryonic stem cell line that was established from a single donor IVF discarded blastocyst. The cells are cultivated in bioreactors and the product of their secretion is collected, purified and concentrated to a standardized formulation. The secretome contains a mixture of molecules related to immunomodulation, growth, and extracellular matrix remodeling.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence and severity of treatment-emergent adverse events (TEAEs)Time frame: Time Frame: Day 0 to Day 28
  2. Change over time in gait speedTime frame: Time Frame: Day 0 to Day 171

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • National Institute of Clinical Research (NICR)

    Garden Grove, California

  • National Institute of Clinical Research (NICR)

    Pomona, California

  • Johnson Country Clinical Trials (JCCT)

    Lenexa, Kansas

  • Tekton Research

    Wichita, Kansas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.